Table 2.
Scheme of treatment
| Cycle | Week | Treatment group | Control group |
|---|---|---|---|
| 1 | 1 | Chemotherapy (Day 1) | Chemotherapy (Day 1) |
| 2 | Chemotherapy (Day 8) | Chemotherapy (Day 8) | |
| 3 | 125I implantation | / | |
| 4 | / | / | |
| 2 | 5 | Chemotherapy (Day 1) + radiotherapya | Chemotherapy (Day 1) + radiotherapya |
| 6 | Chemotherapy (Day 8) | Chemotherapy (Day 8) | |
| 7 | / | / | |
| 8 | / | / |
/, no chemotherapy.
Treatment group: patients underwent chemotherapy (gemcitabine, 1000 mg m−2 once) on the first and eighth days, repeated every 4 weeks (Q4W); implantation was conducted on the third week (synchronous chemotherapy); three-dimensional (3D) conformal radiotherapy was performed in the fifth week (the beginning of the second cycle of chemotherapy).
Control group: patients underwent chemotherapy (gemcitabine, 1000 mg m−2 once) on the first day and eighth day, repeated every 4 weeks (Q4W); 3D conformal radiotherapy was performed in the fifth week (the beginning of the second cycle of chemotherapy).
a
Radiotherapy continued to the end of the course.